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Abstract: Cholangiocarcinoma (CCA) is a deadly tumor without an effective therapy. Unique 
metabolic and bioenergetics features are important hallmarks of tumor cells. Metabolic plasticity 
allows cancer cells to survive in poor nutrient environments and maximize cell growth by 
sustaining survival, proliferation, and metastasis. In recent years, an increasing number of studies 
have shown that specific signaling networks contribute to malignant tumor onset by 
reprogramming metabolic traits. Several evidences demonstrate that numerous metabolic 
mediators represent key-players of CCA progression by regulating many signaling pathways. 
Besides the well-known Warburg effect, several other different pathways involving carbohydrates, 
proteins, lipids, and nucleic acids metabolism are altered in CCA. The goal of this review is to 
highlight the main metabolic processes involved in the cholangio-carcinogeneis that might be 
considered as potential novel druggable candidates for this disease.  
Keywords: cholangiocarcinoma; mitochondria; OXPHOS; PGC-1α; tricarboxylic acid cycle; fatty 
acids; fatty acid synthase 
 
1. Introduction  
Cholangiocarcinoma (CCA), first identified by Steiner and Higginson [1] belongs to a 
heterogeneous group of malignancies that occur at any point of the biliary tree [2]. It can generate 
from epithelial cells in the biliary tracts (ie cholangiocytes) and peribiliary glands [3] and, possibly, 
from progenitor cells or even hepatocytes [4]. Based on the anatomical site, CCAs is classified in two 
major groups: intrahepatic (iCCA) and extrahepatic (eCCA) CCA [5]. The iCCA is located in the 
intrahepatic biliary tree [5,6] whereas eCCA may rise in the extrahepatic bile ducts [7,8]. CCA is 
characterized by very poor outcome, showing an increase in incidence and mortality rate worldwide 
[9–11]. Potentially curative surgical treatment is restricted to the small subset of patients with early 
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stage disease (approximately 35%). At present, the available medical therapeutic treatments for 
advanced or metastatic CCA have limited beneficial efficacy [12].  
Several risk factors, related to chronic biliary inflammation and/or cholestasis, such as primary 
sclerosing cholangitis, have been associated with higher risk of CCA development [13]. Chronic 
hepatitis B and C, cirrhosis, alcohol excess, smoke, obesity and diabetes are mainly associated with 
the development of CCA [9,14]. Several epidemiological reports have shown an increase in global 
occurrence (up to 10 folds) and mortality for iCCA, whereas the incidence for eCCA remained either 
unchanged or slightly decreased [15–19]. CCA is mainly diagnosed in an advanced clinical stage of 
the disease, when curative treatment is generally unsuccessful [20]. This is in part due to the lack of 
clinical manifestation of the tumor in the early stage, especially in case of iCCA, and in part to the 
absence of specific and sensitive biomarkers. To reduce global mortality from cholangiocarcinoma, 
efforts must be multifaceted and focus on prevention, early identification of high-risk individuals 
and prompt diagnosis as well as molecular based targeted therapies for established disease [14]. 
In this scenario, the concept of tumor metabolism is worth particular interest for several 
reasons: (i) metabolic modification is a well-known hallmark of cancer, (ii) oncogenes drive 
alterations in cancer metabolism, (iii) metabolites can control gene and protein expressions, and (iv) 
metabolic proteins and/or metabolites represent diagnostic and prognostic biomarkers [21–25]. 
Indeed tumour cells have unique metabolic and bioenergetic features, allowing them to survive in 
poor nutrient environments and maximize cell growth [22]. Besides glucose metabolism, many other 
different metabolic pathways that involve carbohydrates, proteins, lipids and nucleic acids are 
deregulated in cancer cells. Furthermore, tumour cells are able to shift between different metabolic 
pathways depending on their energetic needs, environmental stress and other factors. Due to the 
high heterogeneity in the metabolic pathways that occur in different tumors, and even inside the 
same tumour [26], this review will highlight the main metabolic processes that occur in CCA 
progression. 
2. Glucose Metabolism and CCA 
The first reported example of a reprogrammed metabolic pathway in cancer is the Warburg 
effect or aerobic glycolysis [27,28] by which tumour cells mainly convert pyruvate to lactate through 
glycolysis even when oxygen is abundant [26]. The increase in glycolytic flux allows glycolytic 
intermediates to supply secondary pathways in order to satisfy the metabolic demands of 
proliferating cells [27]. Warburg effect is in large part induced by the transcription factors hypoxia 
inducible factor 1 alpha (HIF-1α) and c-Myc but also, in lesser extent, by other signaling pathways, 
such as the phosphatidylinositol 3-kinase (PI3K)-Akt mammalian target of rapamycin (mTOR) 
signaling, and the activation of oncogenes and inactivation of tumor suppressors [26]. 
Recently, it has been recognized that Warburg effect in cancer cells is not a general 
phenomenon. Indeed, it has been described also a “reverse” Warburg effect, by which tumour cells 
induce oxidative stress in surrounding stromal fibroblasts, that activates aerobic glycolysis with 
production of high levels of lactate, which is exported out and recaptured by the tumor. On turn, 
cancer cells convert the lactate back into pyruvate, which can be used in the tricarboxylic acid (TCA) 
cycle to fuel oxidative phosphorylation. This theory of “lactate shuttle” between cancer and stromal 
cells proposes the involvement of the stroma in influencing tumour metabolism [29–32].  
A strict dependence of CCA cells on glucose is proved by several papers reporting an increase 
in the expression levels of the glucose transporter GLUT-1 associated to this disease. Recently Kubo 
Y. et al., described that the survival of patients with GLUT-1–positive tumors were significantly 
poorer than those of patients with GLUT-1–negative ones. Moreover, GLUT-1 silencing was able to 
decrease migration and invasion of CCA cells [33]. Coherently, also Ikeno Y et al., observed a 
significantly poorer survival of patients with high GLUT-1 expressing CCA with respect to patients 
with low GLUT-1 expression [34]. Other authors suggest that CCA cells are heavily dependent on 
glucose consumption. Suzuki H. et al., showed that GLUT-1 expression correlates with 
18F-2-fluoro-2-deoxy-D-glucose uptake in the primary iCCA. Furthermore, high numbers of 
GLUT-1-positive cells in the tumor samples were found in patients with poorly differentiated 
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carcinoma, confirming a correlation between GLUT-1 expression and histological differentiation [35] 
(Table 1). 
 
Table 1. Major altered metabolism pathways in cholangiocarcinoma. 
 
Metabolic 
Pathways 
Metabolic Target Effects on Cholangiocarcinoma (CCA) Reference 
Glucose 
metabolism 
GLUT-1 
upregulation  
Correlation with in vitro CCA cell invasion. 
Correlation with larger tumor size, poor 
differentiation, metastasis and poor prognosis 
of CCA. 
[33–35] 
PPP upstimulation 
Sustainment of both the antioxidant capacity 
of CCA cells and cisplatin resistance. 
[36] 
PDK overexpression 
High serum PDK3 levels correlate with short 
survival of patients with CCA. PDK1 
expression promotes glycolysis and CCA cell 
proliferation. 
[37]  
SIRT3 effects 
mediated by HIF1α/ 
PDK1/PDHA1 
pathway 
Decrease of SIRT3 expression induced the 
glycolytic flux through the hypoxia inducible 
factor α (HIF1α)/PDK1/ PDHA1 axis, 
promoting CCA progression. 
[38] 
Deregulation of 
PI3K-AKT-mTOR 
signaling 
Protein overexpression and activation of PI3K 
have been associated with tumor progression, 
differentiation, nodal involvement and 
reduced OS. 
Upregulation of activated form of AKT have 
been reported in neoplastic cells compared to 
the surrounding normal tissue; Increased 
mTOR gene copy number and elevated 
phospho-mTOR levels have been described in 
biliary cancer specimens in comparison to the 
adjacent normal or dysplastic epithelium. 
PTEN loss has been related to poor tumor 
differentiation, nodal involvement and 
shorter survival in CCA. 
[39–42] 
SIRT2 
overexpression 
SIRT2 and its downstream target cMYC, were 
overexpressed both in human CCA cell lines 
and in 48 CCA samples compared to adjacent 
tissues, The SIRT2/cMYC pathway is able to 
reprogram CCA metabolism through 
inhibition of OXPHOS and activation of SSP to 
counteract ROS production, thus protecting 
CCA cells from oxidative stress-induced 
apoptosis. 
[43] 
UCP2 
overexpression 
Up-regulation of UCP2 sustains the EMT and 
cell invasion of CCA cells. [44] 
FXR 
downregulation 
Initiation and progression of CCA, and the 
downregulation of FXR expression could 
promote cancer development, modulating the 
energy metabolism of CCA cells. 
[45] 
PPAR-α 
upregulation 
Tumor occurrence and progression in CCA 
patients with. 
[46,47] 
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IDH1 and IDH2 
mutations 
Increase of glucose uptake and glucose 
metabolism as well as upregulation of some 
metabolites in TCA cycle. Upregulation of 
PFKP. 
[48] 
Mitochondrial 
metabolism 
PGC1α upregulation  Promotion of CCA metastasis both in vitro and in vivo. [49] 
Sirt1/FOXO1 
stimulation 
Involvement in autophagy and mitochondrial 
dysfunction in CCA cells. 
[50] 
Lipid 
metabolism 
FASN 
down-regulation 
In human and mouse iCCA tissues FASN 
expression was down- regulated respect to 
non-tumor adjacent tissues. 
[51] 
FA transporter 
(SLC27A1) 
overexpression 
SCL27A1 silencing in CCA cell lines led to a 
decrease of cells growth. 
[52] 
FA transporter 
(FABP5) over 
expression 
Correlation with worse prognosis in eCCA. [53] 
COX-2 upregulation Promotion of CCA growth and invasion. [54–58] 
Protein 
metabolism 
Glutamine depletion  
Strong depletion: induction a cessation of 
proliferation or cell death (in vitro addiction 
to glutamine). 
Gradual reduction: eCCA cells (EGI-1 and 
TFK-1) could proliferate under long-term 
glutamine withdrawal overcoming their 
addiction to glutamine. 
[59] 
ASS deficiency 
Reduction of arginine in the surrounding 
tumor cells could lead to a reduction in CCA 
cell proliferation. 
[60] 
LAT1 
overexpression 
Activation of mTOR pathway thus affecting 
cell proliferation and viability. 
[61–63] 
Iron 
Metabolism 
TfR1 high 
expression  
Contribution to CCA progression and poorer 
clinical outcomes. 
[64] 
Ferritin high 
expression Negative prognostic index for CCA patients. [65] 
Fpn reduced mRNA 
levels 
Reduction of iron release, in tumor cells of 
CCA patients sample compared to matched 
surrounding liver, suggests that elevated iron 
content is a negative prognostic factor. 
[65] 
Along these lines, Saengboonmee C. et al., [66] clearly reported a direct link between high 
glucose levels in culture media and CCA cell aggressiveness, in term of increased rates of cell 
proliferation, adhesion, migration and invasion with respect to CCA cells cultured in normal 
glucose. Indeed, high glucose levels stimulated both the phosphorylation and the nuclear 
translocation of the signal transducer and activator of transcription 3 (STAT3). In turn, STAT3 
up-regulated the transcription of downstream target genes associated with an aggressive phenotype, 
including cyclin D1, vimentin and matrix metalloproteinase-2. Moreover, tumor tissues from CCA 
patients with diabetes mellitus showed increased levels of phospho-STAT3, confirming the link 
between high glucose patient blood and STAT3 activation. In agreement, glucose reduction or 
STAT3 inhibition reduced the proliferative effect on CCA cells [66]. More recently, the same authors 
reported the effects of high glucose concentrations on O-GlcNAcylation protein expression and 
metastatic potentials of CCA cells. Indeed, Phoomak C. et al., [67] described a marked increase of 
migration and invasion of highly metastatic CCA cell lines when cultured in high glucose medium. 
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In this condition, high glucose uptake may support glucose flux through the hexosamine 
biosynthesis pathway (HBP) to produce uridine diphospho-N-acetylglucosamine, a substrate for 
glycosylation, such as O-GlcNAcylation. The flux of the HBP can be regulated by the expression of 
the rate-limiting enzyme, glucosamine-fructose-6-phosphate amidotransfrase (GFAT), whose levels 
are upregulated in CCA cell lines maintained in high glucose condition and in tissue samples from 
patients correlated with high levels of O-GlcNAcylated proteins. Interestingly, both 
O-GlcNAcylation of vimentin and its stability were increased in CCA cells cultured in high glucose 
and correlated with improved migratory abilities. Conversely, administration of a GFAT inhibitor 
suppressed glucose-induced O-GlcNAcylation, vimentin expression and reversed tumor cell 
invasion [67].  
In keeping with an amplified flux of glycolysis, several evidences suggest an increase of lactate 
levels, the final product of the Warburg metabolism, in CCA. Indeed, increased expression of 
LDH-A, the nicotinamide adenine dinucleotide (NADH)-dependent enzyme that catalyses the 
conversion of pyruvate to lactate, was associated with shorter survival of CCA patients [68]. In line, 
a study conducted by Yu Y et al., showed that lactate dehydrogenase A (LDH-A) was overexpressed 
in 52 of 54 (96%) paraffin-embedded cancer tissues from iCCA patients. Moreover, LDH-A silencing 
inhibited cell growth and promoted HUCCT1 cell death [69]. 
The pentose phosphate pathway (PPP), that directs glucose flux to produce nicotinamide 
adenine dinucleotide phosphate (NADPH) and ribose-5-phosphate, is crucial in CCA metabolism. 
Qu X et al., [36] demonstrated that, in human CCA QBC939 cells, cisplatin resistance was linked to a 
high ability to uptake glucose, to generate lactate and to increase the activity of PPP. Indeed, PPP 
stimulation can be related to an improved flow of autophagy and to an increase in the antioxidant 
capacity of QBC939 cells, sustaining drug resistance. In line, autophagy inhibition, strongly 
decreased glucose-6 phosphate dehydrogenase activity, the first enzyme of PPP, and reduced both 
the NADPH/NADP and reduced glutathione/oxidized glutathione ratio in QBC939 cells. These 
events caused a drop in the antioxidant capacity of QBC939 cells and a consequent burst of 
intracellular reactive oxygen species (ROS), leading to an increased sensitivity to cisplatin treatment 
[36] (Table 1). 
Other studies support the up-regulation of Warburg metabolism in CCA: pyruvate 
dehydrogenase kinases (PDKs) are Ser/Thr kinases that phosphorylate/inactivate mitochondrial 
pyruvate dehydrogenase, thus decreasing the oxidation of pyruvate in the tricarboxylic acid (TCA) 
cycle and increasing the Warburg effect [70]. Sanmai S. et al., [37] demonstrated that PDK1, PDK2 
and PDK3, were significantly overexpressed in 15 CCA tissues compare to normal ones. Moreover, 
PDK3 expression levels were considerably higher in CCA sera compared with the benign biliary 
diseases and healthy groups. In agreement, PDK3 levels correlated with a short survival time in 
CCA [37]. Overall, these data suggest that inhibition of mitochondrial metabolism and hence the 
sustenance of the glycolytic flux can be fundamental in CCA growth. 
Also Xu L., et al., pointed out a central role of PDK regulation in CCA: in this manuscript the 
authors demonstrated that in CCA the decrease of SIRT3 expression induced the glycolytic flux 
through the hypoxia inducible factor α (HIF1α)/PDK1/pyruvate dehydrogenase (PDHA1) axis, 
promoting tumor progression. In particular, SIRT3, a NAD+ dependent deacetylase, inhibited the 
Warburg effect through HIF1α deacetylation/destabilization. Indeed, it is known that lysine 
acetylation is able to regulate the stability of several proteins, including HIF1α. Reduced HIF1α 
stability inhibits glycolysis and down-regulates PDK1. The authors showed that in CCA cells, as 
well as in both tissue samples and in a xenograft model, SIRT3 was downregulated and the 
glycolysis enhanced. Conversely, the induction of SIRT3 was able to efficiently reduce tumor 
proliferation via an anti-Warburg effect mediated by the HIF1α/PDK1/PDHA1 pathway [38] (Table 
1).  
Overall these data highlight a marked increase in the glycolytyic flux and in lactate production 
of CCA cells with respect to benign ones. The enhancement of these metabolic pathways may be 
instrumental for cancer cells to acquire epithelial to mesenchymal transition (EMT) markers for 
tumor progression as well as to sustain divergent pathways, such as PPP, in order to guarantee both 
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biosynthetic intermediates to mantain cell proliferation and the antioxidant capacity to counteract 
oxidative stress [36,66,67].  
Despite these data showing a marked dependence of on Warburg metabolism, Dan Li et al., 
demonstrated that PGC1α overexpression reversed the effect and increased pyruvate flux into the 
mitochondria by up-regulating both pyruvate dehydrogenase E1 alpha 1 Subunit and mitochondrial 
pyruvate carrier 1 expression. These events induced mitochondrial biogenesis and the metabolic 
switch to oxidative phosphorylation (OXPHOS), finally facilitating CCA cells migration and 
invasion [49]. Collectively all these data suggest a great ability of CCA cells to shift between different 
metabolic pathways in order to adapt to environmental changes and to survive. Probably the 
achievement of an OXPHOS metabolism is mandatory to acquire a more aggressive phenotype of 
CCA cells, facilitating the maintenance of stemness features and the improvement of the metastatic 
abilities. Thus, we may suppose that Warburg metabolism and OXPHOS contribute at different 
times or on distinct subpopulation during CCA progression. This evidence could also explain the 
conflicting data concerning the use of Metformin, an inhibitor of the mitochondrial respiratory chain 
(complex I) and hence of OXPHOS, with the onset/development of CCA. 
In particular, it has been observed that Metformin significantly reduced the risk of iCCA in 
diabetic patients by 60% [71,72]. In keeping, also Jiang X. et al., proved that in a xenograft tumor 
model, Metformin significantly inhibited cell growth in vivo, resulting in decreased tumor volume 
and weight [73]. Moreover, CCA patients treated with Metformin showed reduced tumor size and 
improved postoperative survival [73]. On the contrary, Yang Z. et al., [74] have shown that 
Metformin, even if it is able to reduce cancer cell proliferation and to induce cell cycle arrest, did not 
improve the survival of CCA patients with diabetes [75]. 
Thus, further studies are still required to clarify whether Metformin as well as other metabolic 
drugs could be successfully used in clinic for CCA treatment.  
3. Lipid Metabolism in CCA 
The largest part of normal tissues obtains lipids through the uptake of free fatty acids (FFAs) 
and lipoproteins from the bloodstream. Nevertheless, it has been described that many cancers 
showed a reactivation of de novo lipid synthesis, together with an increased expression of several key 
enzymes [76–80] similarly to embryonic tissue. 
However, the role of fatty acid synthase (FASN) in the liver is different in HCC and CCA 
development. Li et al., [81] have demonstrated that in hepatocellular cell lines, FASN silencing 
strongly affected proliferation rate, together with apoptosis increase [81]. Moreover, in a 
hydrodynamic injection mouse model FASN downregulation totally abrogated AKT-dependent 
hepatocarcinogenesis [81], thus FASN plays a key role in HCC development. Nevertheless, in 
human and mouse iCCA tissues FASN expression was down- regulated respect to non-tumor 
adjacent tissues. Indeed, it has been observed that in AKT/Ras mice, which develop both HCC and 
iCCA, FASN knocking-down prevented only HCC onset [51,82] (Table 1).  
Although lipid metabolism is pivotal for tumor development, CCA seems to be totally 
independent on de novo fatty acids (Fas) synthesis [81]. Indeed Li et al., [81] have further analyzed the 
involvement of exogenous FAs uptake. They demonstrated how the deprivation of lipoprotein in 
culture media highly inhibited CCA cells growth [81]. In addition, the expression levels of FAs 
transporters such as cluster of differentiation 36 (CD36) and solute carrier family 27 member 1 
(SLC27A1) were upregulated in AKT/notch-intracellular domain liver tumor tissues. These results 
were confirmed in human iCCA samples, where SLC27A1 was overexpressed respect to normal 
tissues. Moreover, SCL27A1 silencing in both HUCCT1 and HuH28 cell lines led to a decrease of 
cells growth [52]. This reduction of CCA cells proliferation also synergized with FASN knocking 
down [81] (Table 1).  
Many evidences have demonstrated that FAs are actively transported through cell membrane 
by specific proteins, the fatty acid transport proteins (FATPs). In the liver, the main proteins 
involved in this transport are FATP2, FATP1 and FATP5, the fatty acid binding proteins (FABP1, 
FABP4, and FABP5), and the translocase CD36. In particular, FABP5 seems to play distinct role in 
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iCCA and eCCA. A recent research suggests that FABP5 upregulation characterizes eCCA, reflecting 
its worse prognosis respect to iCCA. This difference may be due to distinct embryological tissues 
origin and histological location during carcinogenesis [53] (Table 1).  
Recently, it has been demonstrated that adipocytes contribute to EMT, invasion, proliferation 
and progression, in several cancer types [83–87]. Nie et al., [88] found that co-culture with 
adipocytes led CCA cells to express mesenchymal biomarkers overexpression and cell-to-cell 
adhesion alteration. The acquisition of these mesenchymal markers in CCA cells could be due to 
adypocite-derived FAs. In fact, they showed that the adipocyte-derived FABP4 mediated migration, 
invasion and lipid accumulation in CCA, by shifting FAs between adipocytes and cancer cells [88].   
Even sphingolipids, phospoinositides and eicosanoids derive from FAs. Eicosanoids are 
generated from arachidonic acid that is converted into prostaglandin H2 by cyclooxygenases (COX1 
and COX2) [89]. Recent evidences have demonstrated that prostaglandins (PG) play a key role in 
CCA onset. In fact, in CCA cells and pre-cancerous bile duct lesions has been observed an 
up-regulation of COX-2 levels respect to normal bile duct cells [54–58]. In addition, in CCA cells 
COX-2 overexpression increases PGE2 production, promoting tumor growth [90,91], whereas COX-2 
down-regulation with molecular or pharmacological techniques lowers PGE2 release and prevents 
cancer development and invasion, both in vitro and in vivo tests [55,58,90–94]. Most of the cellular 
functions depend on lipids availability, thus lipid biosynthesis is strictly regulated to avoid lipid 
toxicity and membrane dysfunction [95,96]. 
Importanly, sphingosine-1-phosphate is a pivotal regulator of cell proliferation and survival. 
The enzyme sphingosine kinase (SPHK) converts the sphingolipid sphingosine to S1P, regulating 
cell fate. It has been demonstrated that the isoform 1 of SPHK is involved in tumor proliferation, 
angiogenesis and transformation [97,98]. Chen et al. [99] identified SPHK1 overexpression as a 
marker of poor prognosis for iCCA. They demonstrated that the inhibition of SPHK1 with SK1-I 
induces apoptosis in CCA cell lines, together with growth arrest. Moreover SK1-I intraperitoneal 
injection in CCA xenograft mouse model, leads to a significant suppression of tumor growth [99]. 
This preclinical study has provided a rationale for clinical trials in CCA patients. ABC294640 is an 
inhibitor of SPHK2 (Ki = 9 µM, 3.4 µg/mL) that depletes S1P promoting autophagy and/or apoptosis 
in tumor cells [100–102]. Based on its strong preclinical profile, a first-in-human phase I trial was 
undertaken to analyze the drug’s safety, and to identify the maximum tolerated dose. This study 
was conducted in 22 patients with solid tumors. Interestingly, the best outcome was a partial 
response in CCA patients [103] (Table 2). 
Table 2. Metabolic targeted therapy in CCA. 
Target Glucose Metabolism Reference 
mTOR Everolimus [104–107] 
Sirolimus [108,109] 
Everolimus + CisGem [110] 
PI3K 
 
LY294002 [111] 
Buparlisib [112] 
PI-103 [113] 
Buparlisib + mFOLFOX6 [114] 
Copanlisib ± GemorCisGem [115] 
AKT MK2206 [116] 
IDH1 AG-120 [117] 
AG-221 [118] 
AGI-5198 [48] 
 Lipid Metabolism  
SPHK2 ABC294640 [100–103] 
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HMGCR Simvastatin, Atorvastatin [119] 
 Protein Metabolism  
LAT1 2-aminobicyclo-(2,2,1)-heptane-2-carbox
ylic acid 
[62] 
JPH203 [63] 
ASS ADI-PEG 20 [120,121] 
In addition, statins are a class of drugs that inhibiting HMG-CoA reductase, lead to a reduction 
of serum cholesterol. Several studies have demonstrated that statins are also able to inhibit growth 
and induce apoptosis in several cancer cells. Buranrat et al., [119] showed that Simvastatin and 
Atorvastatin exert an antiproliferative action by inhibiting HMG-CoA reductase and p21 activation. 
Moreover, these statins induced CCA cell death acting through caspase 3 and cytochrome c, 
inhibited cell migration and reduced colony formation ability of CCA cell lines [119] (Table 2). All 
these data suggest that statins could be also used for cancer chemoprevention or chemotherapy [8]. 
4. Protein Metabolism and CCA 
Usually cancer cells metabolize glucose to produce ATP through aerobic glycolysis but they 
have to use other energy sources such as glutamine to satisfy fast proliferation [122]. 
Glutamine is a non-essential ammino-acid, which plays a critical role in cell growth and 
proliferation acting in the synthesis of other non-essential amino acids, in the modification of 
chromatin, in the anti-oxidative defense, in the synthesis of nucleotides as nitrogen donor and in the 
refueling of the TCA cycle intermediate (anaplerosis) [59]. While the role of anaplerosis has been 
demonstrated in HCC its role in CCA is unknown [60] (Table 1). 
Due to continuous loss, replenishment of TCA intermediates is necessary in cancer cells, and 
this fact causes increased glutamine consumption. A reduction in extracellular glutamine 
concentration has been demonstrated in most malignancies and it seems to have a role on the cell 
susceptibility to different apoptosis triggers. Indeed cells starving glutamine are more sensitive to 
Fas ligand, tumor necrosis factor-α (TNF-α) and heat shock-mediated apoptosis [122]. 
The role of glutamine has been studied also in CCA. A paper evaluating glutamine level in CCA 
and the effects of its deprivation on therapeutic response has been recently published [59]. The study 
demonstrated a strong depletion of glutamine in the tumor core region of the majority of the 
samples and this reduction was found to induce a cessation of proliferation or cell death (in vitro 
addiction to glutamine). In a later part of the study a gradual reduction of external glutamine 
concentrations has been evaluated. This part of the experiment suggested that eCCA cells (EGI-1 and 
TFK-1) could proliferate under long-term glutamine withdrawal overcoming their addiction to 
glutamine. Moreover, this study demonstrated that double-deprivation stress through cyclic 
hypoxia and nutrient starvation eliminates hypoxia-induced chemoresistance to cisplatin thanks to a 
reduced c-Myc expression [59]. 
Several transporters mediate the passage of glutamine across the plasma membrane and 
mitochondrial inner membrane. L-type amino acid transporter 1 (LAT1), a Na+-independent neutral 
amino acid transporter, is overexpressed and plays a critical role in various human cancers, 
including CCA [61] (Table 1). For this reason, LAT1 has been evaluated as a target of CCA treatment. 
Janpipatkul et al., demonstrated that KKU-M213 cells (CCA cells derived from Thai patients 
with iCCA) treated with 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid had a reduction in 
L-leucine uptake that consequently inhibits mTOR pathway activity and therefore reduces cell 
proliferation and viability. Similar results were obtained with LAT1 knockdown KKU-M213 cells 
[62] (Table 2). 
Yothaisong et al., in another work demonstrated the role of JPH203 in inhibiting LAT1 transport 
activity. This compound suppressed amino acid uptake and CCA cell growth through altering the 
cell cycle distribution patterns and inducing apoptosis [63] (Tables 1 and 2). 
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Arginine is a semiessential amino acid synthesized from citrulline in two steps: 
argininosuccinate synthetase (ASS) converts citrulline and aspartate in argininosuccinate that is later 
converted to arginine by argininosuccinate lyase.  
Argininosuccinate synthetase deficiency has been demonstrated in various malignancies such 
as melanoma, prostate cancer, pancreatic cancer, renal cell carcinoma, HCC and CCA [120].  
Tumor cells that have low ASS expression are unable to synthetise arginine and must depend 
on extracellular arginine. On the basis of this knowledge, it has been hypothesized that a reduction 
of arginine in the surrounding tumor cells could lead to a reduction in cell proliferation. ADI-PEG 20 
is a cloned arginine-degrading enzyme (arginine deaminase) conjugated with polyethylene glycol 
that degrades arginine to citrulline. The role of ADI-PEG 20 has been evaluated in patients with 
advanced HCC with good results in a phase II trial, whereas the phase III trial did not met its 
primary endpoint [121] (Table 2). ADI-PEG20 has been studied also in patients with CCA where the 
treatment significantly inhibited growth of RmCCA-1 and HuCCA cells by decreasing both the 
percentage of viable cells and the proliferative activity in a dose-dependent manner [120].  
Arginine is also a substrate of the urea cycle, a metabolic process that occurs exclusively in the 
liver. The urea cycle transforms ammonia in urea that is less toxic for the organism. Various studies 
have shown that the urea cycle is altered both in HCC and CCA. A suppression of members of the 
urea cycle, probably due to epigenetic alterations, has been demonstrated in HCC [123]. 
Changes in the expression and metabolism of other amino acids compared to healthy patients 
or patients with other malignancies have also been reported in CCA. 
Murakami et. al., demonstrated that a multi-omics approach, integrating metabolomic and 
transcriptomic datasets, was able to distinguish between iCCA and HCC tumours. Regarding amino 
acids metabolism four amino acids (Lys, Pro, Leu and IIe) were more diversely expressed in 
iCCA/iCCA-non tumor than in HCC and HCC-non tumor [124]. 
5. CCA and Iron  
Iron is necessary for cellular replication and growth, so it is an essential element for life. 
However, excess iron can facilitate the formation of the most reactive and toxic forms of oxidants 
through the Fenton reaction [125]. The regulation of cellular iron homeostasis is due to different 
proteins: the transferrin receptor (TfR1), responsible for transferrin-bound iron up-take, major 
players in ferroportin (Fpn), the only cellular iron exporter, and ferritin, the iron store protein [126]. 
An association between high body iron content and cancer in the general population has been 
demonstrated [127], as well as positive relation between increased body iron stores and the risk of 
liver cancer [128] (Table 1).  
It has been shown also a relationship between liver iron and CCA. In particular, it was 
demonstrated that high expression of TfR1, with consequent iron uptake, contributes to CCA 
progression and poorer clinical outcomes [64] (Table 1). Accordingly, it has been showed that high 
ferritin expression in epithelial cells from CCA patients is a negative prognostic index (6) (Table 1). 
Moreover, in line with these findings, it has been found significantly reduced Fpn mRNA levels, that 
means reduced iron release, in tumor cells of CCA patients sample compared to matched 
surrounding liver, suggesting that elevated iron content is a negative prognostic factor [65] (Table 1).  
In general, the alterations of iron trafficking in cancer cells lead to iron acquisition or decrease 
iron release (the high iron needs of tumor cells to sustain cell proliferation) and it has been shown 
that these alterations of cellular iron metabolism are dependent on the direct action of tumor 
suppressors and oncogenes [129]. 
Recently, it has also been shown that increased iron retention in CCA-cancer stem cells (CSCs) 
could be a novel metabolic factor involved in CCA growth [65]. In particular, it has been shown that 
CSCs have a phenotype symptomatic of elevated cellular iron content and oxidative stress; increased 
iron levels are accompanied by important changes in the expression of stemness markers, such as 
EMT markers, in these cells that can be reversed by iron removal. This finding was mirrored by data 
showing a trend toward shorter survival in CCA patients with iron levels. 
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Finally, it has to be noted that CCA-CSCs, despite higher levels of iron and ROS, seem to be less 
susceptible to the ferroptosis, a recently characterized mechanism which causes cell death through 
iron-dependent ROS production and lipid peroxidation [130], than CCA cells. This finding could be 
perhaps due to the well-known CSC resistance to various types of chemoterapeutic agents.  
All the observations reported here regarding CCA and iron seem to suggest a hopefully 
translation into an effective adjunct therapeutic approach based on iron deprivation that should be 
provided. 
6. Molecular Aspects Underlying CCA Metabolism 
In recent years, an increasing number of studies have elucidated how metabolism is altered in 
cancer cells, based on observations that components of signal transduction pathways frequently 
regulate cell metabolism (Figure 1). Tumor cells select mutations that enhance signal transduction 
through pathways that converge upon a set of metabolic processes that contribute to tumorigenic 
process. The rewiring of cancer cells metabolism includes abnormalities in glucose homeostasis and 
other nutrients such as aminoacid and lipid and impairment of mitochondrial function [22].  
 
Figure 1. Crucial signaling pathways in CCA metabolism. The PI3K/AKT/mTOR pathway is an 
essential modulator of cell metabolism, growth and survival in CCA. Activating mutations of gene 
coding for the p110a and p85a subunits of PI3K and loss of the phosphatase and tensin homolog 
(PTEN) have been reported in CCA. Moreover, it has been shown the overexpression of downstream 
mTOR effectors, such as p70S6K and p-4E-BP1. SIRT2/cMYC pathway is overexpressed in CCA cell 
lines and mediates the activation of the PDHA1 by inhibition the OXPHOS as well as the activation 
of SSP that acts against ROS production. During CCA progression increase lactate levels while 
pyruvate levels decrease. Moreover, cMyc induces an increase of LDH and PKM2 expression, which 
afterwards reduces pyruvate levels. Being the pyruvate an HDAC3 inhibitor, a reduction of its levels 
removes HDAC3 inhibition and promotes cMyc overexpression. Sirt1/FOXO1 pathway is involved 
in autophagy and mitochondrial functions. UCP2 promotes CCA development through AMPK 
pathway. FXR expression is downregulated in human tissues and CCA cell lines inducing tumor 
progression by modulating cellular metabolism. PPAR-α is overexpressed in CCA patients and 
modulates several genes involved in glucose and lipid metabolism as well as immune responses. All 
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these alterations induce the activation of pathways that promote CCA progression through a 
reprogramming of cellular metabolism. 
6.1. PI3K-AKT-mTOR Signaling Pathway  
The signaling pathway PI3K-AKT-mTOR is one of the most frequently altered pathways in 
human cancer [131] and plays a critical role in tumorigenesis through the modulation of cellular 
metabolism, including glucose homeostasis, nutrients uptake and utilization. Its deregulated 
activation supports enhanced cancer cell growth and proliferation and drives tumor initiation and 
progression. The role of PI3K/AKT/mTOR pathway in human CCA has been assessed both in vitro 
and in vivo. The most common alterations include activating mutations and overexpression of the 
PI3K genes (PIK3CA and PIK3R1) that encode respectively for the p110a and p85a subunits [132]. 
PI3K is a lipid kinase that phosphorylates the 3′-hydroxyl group of the inositol ring of 
phosphatidylinositol to generate 3′-phosphoinositides [39]. Uncontrolled activation of this kinase 
causes accumulation of transit signals responsible for pathway triggering. Protein overexpression 
and functional activation of PI3K have been associated with tumor progression, differentiation, 
nodal involvement and reduced overall survival (OS) [40]. Positive immunostaining for 
unphosphorilated and phosphorylated form of AKT have been reported in human CCA specimens, 
with higher rates in neoplastic cells compared to the surrounding normal tissue [40]. Increased 
mTOR gene copy number and elevated phospho-mTOR levels have been described in biliary cancer 
specimens in comparison to the adjacent normal or dysplastic epithelium [41]. Moreover, several 
studies reported overexpression of downstream mTOR effectors in CCA. For example, high p70S6K 
expression has been associated with poor tumor differentiation [41] and high p-4E-BP1 level has 
been correlated with poor prognosis in a CCA patient’s cohort [41]. The lipid phosphatase and 
tensin homologous (PTEN) is responsible for negative regulation of the pathway and inactivating 
mutations or deletion of PTEN lead to uncontrolled activation of PI3K/AKT/mTOR signaling. In 
fact, PTEN loss has been related to poor tumor differentiation, nodal involvement and shorter 
survival in CCA [42] (Table 1). Finally, several growth factor receptors have been involved in 
cholangiocarcinogenesis via PI3K/AKT/mTOR pathway. For example, EGFR/HER2-dependent 
PI3K/AKT phosphorylation has been demonstrated in CCA cell lines and human CCA tissue 
samples [133,134]. The PI3K/AKT/mTOR pathway acts downstream of insulin growth factor 
receptor 1 (IGFR1) in CCA tissues. Indeed IGFR1 inhibitors NVP-AEW541 [135] and BMS-536924 
prevented AKT activation and exerted antiproliferative effects in CCA cells and in a xenograft CCA 
mouse model [136].  
The studies described in this paragraph showed mutations, gene copy number alterations and 
aberrant protein phosphorylation of the key players of this pathway in CCA. These alterations lead 
to PI3K/AKT/mTOR pathway activation, which in turn triggers anabolic processes such as mRNA 
translation, protein synthesis and post-translational modulation of metabolic enzymes and switch to 
aerobic glycolysis, supporting enhanced growth, proliferation, chemoresistance.   
Pre-clinical studies demonstrated that the following PI3K inhibitors, LY294002, Buparlisib 
(BKM120) and PI-103 have significant in vitro activity against CCA cells.  
LY294002 inhibited cell proliferation, invasiveness and EMT [111] by decreasing p-AKT and 
p70S6K levels.  
Buparlisib demonstrated important anti-proliferative activity in either mutant or wild-type 
KRAS CCA cells [112], while the inhibitor PI-103 affect cell proliferation in a xenograft CCA mouse 
model [113]. Clinical reports on the activity of PI3K inhibitors in CCA are limited. A Phase I trial 
evaluated the activity of mFOLFOX6 (modified Folinic acid/5-Fluorouracil/Oxaliplatin) combined 
with Buparlisib in 17 patients with advanced refractory gastrointestinal tumors (4 of whom were 
CCAs). The maximum tolerated dose (MTD) (primary endpoint) of Buparlisib was established at 40 
mg. Only 8 patients out of 17 were treated for at least two cycles (8 weeks) and were evaluable for 
response. At the end of this study the authors concluded that the combination of mFOLFOX6 with 
Buparlisib resulted in increased toxicity compared to either treatment alone and did not prove 
efficacious in treatment of advanced refractory biliary tract malignancies ([114], Table 2). 
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In addition, Copanlisib is a pan-class I inhibitor of PI3K with predominant PI3K-α/δ activity 
with clinical activity and manageable safety when administered as monotherapy in a phase II study. 
Kim and colleagues showed the results of a phase I study to determine the safety, tolerability and 
recommended phase II dose of Copanlisib in combination with Gemcitabine or with Cisplatin plus 
Gemcitabine (CisGem) in patients with advanced solid malignancies, including CCA [115]. 
Concerning AKT inhibitors the allosteric inhibitors (MK2206) or adenosine triphosphate 
(ATP)-competitive molecules proved to be effective to impair cell proliferation, survival and in 
different CCA cell lines [137,138]. 
MK2206 as an orally administered single agent was evaluated at the weekly dose of 200 mg in 
a Phase II study enrolling 8 patients affected by advanced, pretreated CCAs. None of the 8 patients 
had an objective response and only two patients achieved stable disease (25%) at 12weeks ([116], 
Table 2).  
The pathway of mTOR was assessed in vitro using an mTOR inhibitor, Everolimus, showing 
dose-dependent decrease of cell proliferation by this molecule [139]. A phase I study reported that 
Everolimus achieved 50% disease-control-rate in a subgroup of 22 advanced CCA patients ([104], 
Table 2). Subsequently a phase II study, in which patients with advanced CCA were enrolled, used 
Everolimus as a treatment option reporting an OS of 9.5 months [105]. At the same time in a phase II 
Italian study with Everolimus 39 patients with advanced and pre-treated CCA had progression-free 
survival (PFS) of 3.2 months, and OS of 7.7 months [106] while an Australian phase II study with 
Everolimus, conducted on patients with advanced CCA, showed objective response rate of 12 % and 
PFS of 6.0 months. Recently in 27 unselected patients, Everolimus displayed clinical activity as 
first-line monotherapy in advanced CCA with PFS of 5.5 months and OS of 9.5 months [105]. In 
another phase II study that aimed to evaluate the activity of Everolimus in 10 patients with PIK3CA 
amplification/mutation or PTEN loss refractory solid cancer, only one patient with CCA with PTEN 
loss experienced disease control ([107], Table 2). Concerning other mTOR inhibitors, Rizell reported 
a cohort of Sirolimus used in patients with HCC (n = 21) and iCCA (n = 9). Three (33%) of nine 
patients with iCCA achieved stable disease after Sirolimus treatment [108]. In a clinical study 
enrolling patients with PIK3CA mutant/amplified refractory solid cancer, Sirolimus failed to 
demonstrate the clinical benefit in a patient with hilar CCA (PIK3CA E545K mutation) who 
experienced disease progression following the second cycle of Sirolimus with PFS of 0.9 months 
([109], Table 2). Regarding clinical trials using mTOR inhibitors and standard treatment, the only 
published study was performed to determine the MTD of different combinations of Everolimus and 
chemotherapeutic agents ([110], Table 2).  
Despite several studies showed encouraging results more extensive investigations are 
necessary to elucidate the efficacy of mTOR inhibitors in the treatment of CCA. 
6.2. SIRT2/cMYC Signaling Pathway 
Recently, another pathway, sustained by a divergence of the glycolytic flux, has been described 
to have a crucial role in promoting CCA proliferation. It is known that the glycolytic intermediate 
3-phospho-glycerate can be shunted to the serine synthesis pathway (SSP) to sustain an antioxidant 
response. Indeed, a metabolic reprogramming of CCA cells towards the production of anti-oxidant 
molecules may support cancer cell growth through the reduction of tumor oxidative stress [43]. Xu 
L. et al., [43] observed that the histone deacetylase sirtuin 2 (SIRT2) and its downstream target 
cMYC, were overexpressed both in two human CCA cell lines (HUCCT1 and RBE) with respect to 
normal bile duct epithelial cells and in 48 CCA samples compared to adjacent tissues. The 
SIRT2/cMYC pathway is able to reprogram CCA metabolism through: i) phosphorylation of the 
PDHA1 and hence inhibition of OXPHOS; ii) activation of SSP to counteract ROS production by 
increasing antioxidant defenses, thus protecting CCA cells from oxidative stress-induced apoptosis. 
Indeed, CCA patients with elevated expression levels of SIRT2, cMYC, and p-PDHA1 were 
associated with lower survival rates [43]. The same authors showed that CCA cells stabilized a 
positive feedback loop sustaining Warburg metabolism [43]. At this regard, it has been 
demonstrated that CCA cells, through an avid consumption of glucose, decreased the level of 
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pyruvate in favor of increased levels of lactate. Actually, tumour cells induce a MYC-mediated 
increase of LDH and Pyruvate kinase isoenzyme M2 expression levels causing a decrease in 
pyruvate levels. Pyruvate is an inhibitor of the histone deacetylase HDAC3, which deacetylases 
cMYC at the K323 site, promoting its stabilization. Thus cMYC, by decreasing pyruvate levels, 
removes HDAC3 inhibition and sustains a positive feedback loop. This circuitry protects cancer cells 
from apoptosis [140]. Moreover, the high levels of carbon flux supply the increased production of 
metabolic intermediates, giving advantages in a challenging tumor microenvironment [141–143].  
6.3. Uncoupling Protein 2 (UCP2) 
Yu J et al. [44] have produced another recent paper supporting the association of CCA with 
glycolysis. They showed that the uncoupling protein UCP2, promoting the proton leak to decrease 
the electrochemical potential and hence ATP synthesis, was up-regulated in human CCA and this 
event was associated with a worse prognosis. Up-regulation of UCP2 sustains the EMT and cell 
invasion. Indeed, in in vitro experiments they proved that inhibition of UCP2 suppressed cell 
proliferation and migration, reversed EMT, and reduced drug resistance as well as spheroid 
formation. Interestingly, all these events correlated with reduced glycolytic flux, reinforcing the idea 
that UCP2 contributes to the progression of CCA through a glycolysis-mediated mechanism [44] 
(Table 1). 
6.4. Transcription Factor FOXO1 
Autophagy plays a key role in the maintenance of cellular homeostasis. In healthy cells its 
homeostatic activity represents a robust barrier against malignant transformation and control of 
autophagy progression in cancer cells is an effective strategy to halt tumor growth [144]. Impaired 
autophagy could interfere with key cellular processes including energy metabolism control and 
mitochondrial dysfunction [145]. In CCA cell line QBC939, the authors demonstrated that the 
transcription factor FOXO1 regulated both basal and serum starvation-induced autophagy via the 
interaction between Acetylated-FOXO1 and Atg7. FOXO1 silencing or Sirt1 inhibition, affected 
autophagic flux, impaired mitochondrial function and induced apoptosis in a cholangiocarcinoma cell 
line, suggesting a role of Sirt1/FOXO1 pathway in the interplay between autophagy and 
mitochondrial dysfunction in CCA [50] (Table 1). 
6.5. Nuclear receptors: farnesoid X receptor (FXR) and Peroxisome Proliferator Activated Receptor-α 
(PPAR-α) 
The nuclear receptors have bi-functional activities, are capable of binding hormone as well as 
directly activating gene transcription. Nuclear receptors and their coregulators exhibit critical 
functions in the regulation of metabolic processes and they are central regulator of feeding and 
fasting state [146].  
Among nuclear receptors, farnesoid X receptor (FXR) regulates bile acid homeostasis and it is 
activated in the fed state to exert a direct effect on metabolic pathways, including suppression of 
both gluconeogenesis and lipogenesis [147,148]. 
Rather, peroxisome proliferator-activated receptor-α (PPAR-α) is a well-known inducer of 
hepatic fatty acid oxidation in the fasted state and it promotes gluconeogenesis [149]. 
FXR and PPAR-α have opposite functions in metabolic mechanisms, that determine opposite 
effects on gluconeogenesis, indicating extensive functional interactions and conflicting metabolic 
effects. 
The high expression of FXR was observed in tissues exposed to high bile acid concentration, 
including cholangiocytes, and this type of nuclear receptor is also involved in several processes such 
as lipid and glucose metabolism, fibrosis, and regeneration [150–153]. 
Moreover, Erice et al., [45] have recently shown a downregulation of FXR expression in both 
human tissues and CCA cell lines. They have found that the FXR agonist, obeticholic acid (OCA), 
inhibited the orthotopic CCA tumor growth in immunodeficient mice and this was associated with 
decreased expression of proliferation markers such as Ki67 and PCNA. Moreover, in vitro it has 
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been demonstrated that OCA inhibited CCA cell proliferation and migration and these inhibitory 
effects of OCA on CCA cells were associated with decreased mitochondrial energy metabolism [45] 
(Table 1). 
Loss of FXR activity could be an important molecular event in the initiation and progression of 
CCA, and the downregulation of FXR expression could promote cancer development, modulating 
the energy metabolism of CCA cells.  
A further fundamental factor in CCA progression is PPAR-α. In a recent study, there have been 
identified endogenous RNAs which modulated the expression of target genes, which could have a 
role in tumor occurrence and progression in patients with CCA. The analysis performed has 
revealed that the genes identified were strongly linked to metabolism. Pathway analysis has found 
that carbon metabolism, bile secretion, fat digestion, and PPAR signaling pathway were processes 
significantly enriched and played a pivotal role in CCA patients [46] (Table 1). 
Recently, through the meta-analysis of CCA that represents a new systematical multivariate 
analysis tool, there have been identified 25 genes and five pathways associated with type 2 diabetes, 
obesity, and dyslipidemia. All five pathways were associated with the metabolism of lipids. Among 
these pathways, there was PPAR-α signaling which represents a significant modulator of numerous 
genes involved in glucose and lipid metabolism as well as inflammatory processes. PPAR-α in 
human liver determines also the down-regulation of several genes involved in various 
immunity-related pathways [47] (Table 1).  
6.6. Isocitrate Dehidrogenase (IDH)  
Isocitrate dehidrogenase enzymes play an important role in the TCA cycle, catalysing the 
oxidative decarboxylation of isocitrate to α-ketoglutarate, producing carbon dioxide and NADPH 
[26]. Frequent mutations in the IDH1 and IDH2 genes have been shown in different types of cancer, 
including CCA [154,155]. IDH mutations (mIDH) are known as neomorphic mutations, since they 
give a new function to the product of the altered gene. Indeed, they establish a pathway for the 
NAPDH-dependent conversion of the wild-type IDH product, α-ketoglutarate into 
2-hydroxyglutarate (2-HG) [156] with a significant decrease in NADPH production [157] (Table 1). 
2-HG is normally present as two enantiomers, dextrogyre (D) and laevogyre (L). Interestingly mIDH 
preferably provokes an increase in the D-enantiomer of 2-HG rather than the L-enantiomer and 
these forms can be measured in the serum by gas chromatography coupled to mass spectrometry 
[158] or liquid chromatography combined with mass spectrometry [159,160]. 
In the most mIDH, the wild-type IDH function is lost due to mutation of critical amino acid 
residues in the catalytic domain, IDH1 R132 and IDH2 R172, which normally binds the b-carboxyl 
group of isocitrate to start catalysis [156,161].  
In CCA, the most common mutations of IDH1 are R132C (more frequent), R132G and R132L, 
which are distinct from the R132H mutation found in gliomas [155,162,163]; nevertheless, these 
activating alterations have been shown to increase the serum level of 2-HG in cholangiocarcinoma 
[160]. The prevalence of IDH2 mutations in CCA is instead R172K, R172M, and R172G [162]. 
Accumulating evidence identifies 2-HG as an oncometabolite, since it interferes with many 
regulatory pathways involving α-ketoglutarate-dependent dioxygenases, including those 
implicated in epigenetic remodeling and DNA repair [164–166]. Indeed 2-HG hinders the function of 
enzymes that use α-ketoglutarate as a co-enzyme, including histone and DNA demethylases, by 
competitively occupying the same pockets as α-ketoglutarate [167,168].   
Genomic studies reported that mutations in IDH1/2 were found in approximately 10% (range, 
5-36%) of iCCA, whatever the geographical area of the world [154,169–171] while mutations in IDH1 
were linked to iCCA with a prevalence of about 20% in North America [162].  
The histological characteristics of CCA mIDH1 tumors are not well defined: they seem to vary 
from small duct types and unique geographic type fibrosis [172], to a large spectrum of 
histopathology features [155]; the discordancy could be due to the relatively small number of 
analyzed patients for each single study. Intriguingly, mIDH CCA tumors present definite molecular 
characteristics, including low levels of chromatin modifiers, upregulation of mitochondrial genes, as 
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components of the TCA cycle and electron transport chain, and increased copy numbers of 
mitochondrial DNA [155]. Of note, mIDH hypermethylates ARID1A promoter can lower the 
chromatin remodeler expression [155]. A recent study on a large cohort of of iCCA patients (n=496) 
based on occurrence of mutations in IDH, KRAS and TP53 genes, revealed unique mutational, 
structural and epigenetic features, which could facilitate prediction of therapeutic sensitivity for 
each iCCA patient, by evaluating individual genotyping [173]. It has been reported that mIDH 
occured mostly in woman with a percentage of about 60-70%, a higher incidence than in the whole 
CCA population [174], and that three genes resulted often co-mutated with mIDH: ARID1A (22%), 
BAP1 (15,5%) and PBRM1 (13,3%) [174].  
Unfortunately none of the studies on mIDH have showed significant association between the 
presence of these alterations and clinopathological features (OS, PFS or time of progression) [174].  
The high incidence of IDH mutations in numerous malignant tumors has promoted the 
development of specific inhibitor compounds resulting in several clinical trials.  
AG-120 (Ivosidenib), an oral selective inhibitor of mIDH1 characterized by good tolerance, has 
displayed therapeutic activity with reduction of 2-HG levels in various solid tumors, including CCA 
[117]. In CCA patients treated with Ivosidenib, 6-month PFS was 38% and 12-month PFS was 20%; 
56% of patients achieved stable disease and 5% achieved a partial response.  
A follow-up trial in mutated IDH1 CCA patients that are not eligible for curative resection, 
transplantation, or ablative therapies prior to enrollment, is underway (NCT02989857) with 
completion date on 11/01/2019. Patients with IDH2 mutated solid tumors have been enrolled in a 
phase I-II clinical trial evaluating the orally bioavailable compound AG-221, an inhibitor of mutant 
IDH2 (NCT02273739) [118] (Table 2). 
Very recently, it has been reported that IDH1 mutation in CCA enhanced the formation of 
intrahepatic biliary organoids (IBOs) and sped up the glucose uptake and glucose metabolism as 
well as upregulation of some metabolytes in TCA cycle (citrate, fumarate and malate). Interestingly 
platelet isoform of phosphofructokinse-1 (PFKP), a rate-limiting glycolytic enzyme, was also 
upregulated and knockdown of its gene reduced IBOs formation, indicating that the induction of 
glycolysis in mutant IBOs could occur by enhancing the expression of this enzyme. A direct link 
between the IDH 1 mutation and the expression of PFKP was demonstrated by the decrease of the 
protein level in mutant IBOs treated with AGI-5198 (a mIDH1 inhibitor) and the increase of the 
protein level in mutant IBOs treated with 2-HG (Table 2). In addition, mutant IBOs could sustain 
survival in ATP depletion conditions by obtaining ATP through the activation of AMPK. These 
results suggest that IDH mutation drives two-way metabolic rewiring status [48]. (Table 1). 
6.7. Tumor Suppressor p53 
In addition to oncogenes, tumor suppressors, like the p53 transcription factor, can regulate 
cancer metabolism [175]. The p53 canonical activity is related to cell cycle arrest, senescence, 
apoptosis and DNA repair, but recently it has been demonstrated that p53 results also involved in 
regulating cancer metabolism and oxidative stress [176,177]. Indeed loss of this protein causes an 
increased glycolytic flux to induce anabolism and redox balance that ultimately leads to 
tumorigenesis [175]. 
The p53 protein-encoding gene TP53 is mutated or deleted in 50% of all human cancers [22]. 
Particularly in iCCA, while commonly harbors mutations affect IDH1/2, BAP1, KRAS, TP53, SMAD4, 
and ARID1A [178,179]. The p53 inactivation is the most common dysfunction (observed in 37% of 
iCCAs) [180,181], recently revealed as predictor of a poor prognosis [182]. The p53 is also involved in 
eCCA development and serum antibody against this protein was reported to be useful for the early 
detenction of this form of cancer [183,184]. Of note TP53 loss enhanced reprogramming of 
hepatocytes to biliary cells promoting CCA, pointing at p53 as a critical regulator of this process 
[185].  
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6.8. Hif-1α signaling pathway 
Nowadays, hypoxia is widely recognized as a critical tumor-promoting player. Hypoxia exerts 
a selective pressure on cancer cells, promoting the clonal expansion of the most aggressive tumor 
phenotypes. Cellular responses to hypoxia are primarily mediated by the activation of HIFs, i.e., 
helix-loop-helix transcription factors that bind to specific DNA sequences known as 
hypoxia-response elements. HIFs consist of two subunits: α (HIF-1α, HIF-2α, or HIF-3α) and β 
(HIF-1β). Among HIF-α isoforms, HIF-1α is the best characterized, due to its ubiquitous expression. 
HIF-1α is a master regulator of transcriptional response to low oxygen and it is associated with 
resistance to radiotherapies and chemotherapies and poor clinical outcome [186]. HIF-1α promotes 
the transcription of several target genes involved in key cellular processes including glucose 
metabolism [187]. 
In CCA specimens, HIF-1α is typically overexpressed compared to bile ducts of peritumoral 
areas [188], and its high expression was reported as an independent prognostic factor for overall and 
disease-free survival [189] (Table 1). Consistently, in vitro studies clearly demonstrated that 
hypoxia-induced signaling led CCA cells to gain a more malignant phenotype. For instance, 
low-oxygen culture conditions, as well as treatment with cobalt chloride (i.e., a chemical inducer of 
HIF-1α), promoted a substantial increase in CCA cell motility and invasiveness [190,191]. In a recent 
study the authors found that the hepatocyte growth factor (HGF) antagonist NK4 is effective on 
inhibiting CCA cell hypoxic growth and invasion both in vitro and in vivo. In particular, NK4 
inhibited HIF-1α expression and HIF-1-induced CCA cells invasion in vitro and tumor angiogenesis 
in vivo, suggesting an involvement of HGF/MET signaling on the CCA malignant phenotype 
promoted by HIF-1α [192]. Moreover HIF-1α regulated the expression of Rab1a via miR-212-3p. 
Rab1a is a member of RAS oncogene family and its overexpression activates mTORC1 signaling that 
plays a critical role in tumor metabolic reprogramming [193]. It has been demonstrated that Rab1a 
was overexpressed in iCCA tissues and associated with poor prognosis of iCCA patients and 
knockdown expression of HIF-1α under hypoxia condition decreased the expression of Rab1a 
expression while miR-212-3p was increased. Suppression of Rab1a led to lower proliferation rate 
and migration ability both in vitro and in vivo by inhibiting cell cycle and EMT. In conclusion this 
study demonstrates that HIF-1α/miR-212-3p/Rab1a axis, a well-known mTORC1 associated 
signalling, enhances proliferation and migration of CCA cells [194].   
It has been described that HIF-1 is able to stimulate lipid accumulation through HIF-2 protein 
induction, a factor implicated in neutral lipids deposition into lipid droplets [195]. In addition, in the 
liver HIF2 is involved in changing of lipid metabolism in response of VHL lack. The specific 
liver-deletion of VHL in mice lead to steatosis, together with increased lipid droplets formation and 
βoxidation down-regulation [196]. The exact role of these lipid droplets in tumor development and 
survival is not fully understood, but it has been proposed that the storage of triacylglycerides could 
be useful in intermittent hypoxia conditions, since they can be utilized as a quickly available energy 
source after reoxygenation [96]. Although FAs utilization is crucial for cancer cells survival in 
hypoxic condition, indeed it seems that tumor cells preserve a certain grade of ß-oxidation, as shown 
by CPT1C requirement [197]. In addition, it has been demonstrated that hypoxia also stimulated 
FASN expression, through Akt and SREBP1. To regulate FA biosynthesis, hypoxia is able to alter 
lipid composition of tumor cells, by impairing lipid synthesis and modification pathways on one 
hand and modifying exogenous lipids uptake on the other. In fact, a recent study showed how 
hypoxic tumor cells undertake lysophospholipids from the environment to meet the requirement of 
unsaturated FAs [198]. 
7. Future Directions 
Several studies have shown that impaired metabolism in cancer cells may result in the 
generation of an unbalanced metabolically microenvironment [199]. In particular, the metabolic 
effects on immune cell phenotype have recently become of major interest [200–202]. 
Rising evidence have shown that crucial feature of immune cells such as activation, 
differentiation, as well as regulation of immune responses and immunological memory are strictly 
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associated to their metabolic state. For instance, metabolism modulates macrophage polarization 
and consequently their functions. Conventionally, M1 macrophages mediate an inflammatory and 
antitumor response through glycolysis and reduced mitochondrial activity. Conversely, 
anti-inflammatory M2 macrophages show enhanced fatty acid oxidation and high OXPHOS as well 
as more mitochondria [203,204]. In M1 macrophages, glycolysis favours the introduction of the 
carbon flux into the oxidative PPP pathway, which produces NADPH for the generation of ROS via 
NADPH oxidases [205].  
Further, M2 macrophages express specific changes in some metabolic pathways such as 
arginine metabolism that is moved toward the production of ornithine and polyamine by arginase I 
and II instead of citrulline and NO by inducible nitric oxide synthase (iNOS) [205,206]. 
Moreover, fatty acid oxidation supports the pro-tumor potential of M2 macrophages and 
provides a crucial energy source for M2 macrophage polarization. [202]. Additionally, it has been 
observed that the inhibition of fatty acid oxidation in tumor-associated macrophages promotes 
antitumorigenic differentiation and inhibits tumor growth [207]. 
Furthermore several findings indicate a key role of glycolysis in Treg proliferation in the tumor 
setting. Intra-tumoral Tregs show a high glucose uptake [208] and they have high levels of GLUT-1 
on the cell surface, express high levels of glycolysis-related genes, and engage a higher glycolytic 
flux as measured in terms of extracellular acidification rate directly compared to effector T cells 
[209]. These evidences suggest that glycolysis may be involved in the maintenance and proliferation 
of tumor- infiltrating Tregs.  
CCA growth is deeply affected by a multitude of immune cells. However, the consequences of 
the metabolic programming of immune cells on CCA progression are largely indeterminate and 
should be further studied in order to develop more effective combinatorial therapies. 
Owing to the increasing focus of research on immune-modulating therapy options, knowledge 
of the molecular mechanisms underlying immune infiltration of CCA is of growing interest. The 
development of innovative approaches based on generating T cell products for immunotherapy 
requires the acquiring of new knowledge on metabolic aspects that favors anti-tumor function of T 
cells.  
Overall, the emerging interfaces between metabolism and immune response: 
“immunometabolism” may allow identifying metabolic pathways that may modulate the immune 
response during CCA initiation and progression. 
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